Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis
- 31 July 2005
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 4 (7) , 403-412
- https://doi.org/10.1016/s1474-4422(05)70117-4
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Current Disease-Modifying Therapies in Multiple SclerosisSeminars in Neurology, 2003
- Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Selection events operating at various stages in B cell developmentCurrent Opinion in Immunology, 2001
- Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐αBritish Journal of Haematology, 1996
- Clonal selection and learning in the antibody systemNature, 1996
- Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.Proceedings of the National Academy of Sciences, 1996
- Development and Selection of T Cells: Facts and PuzzlesPublished by Elsevier ,1995
- Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon AntibodiesNew England Journal of Medicine, 1988